Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.48 |
| ▸ | CNR1 | P21554 | 10/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7442888 | 0.79 | CNR1 (0.44) | CNR1MAPTSRD5A1SRD5A2 | |
| SCHEMBL30307890 | 0.79 | CNR1 (0.44) | CNR1MAPTSRD5A1SRD5A2 | |
| SCHEMBL763027 | 0.77 | CNR1 (0.46) | CNR1LMNASRD5A1SRD5A2 | |
| SCHEMBL11005283 | 0.77 | CNR1 (0.49) | CNR1MAPTHTTBLMSRD5A1 | |
| SCHEMBL4464683 | 0.77 | MAPT (0.49) | CNR1LMNAMAPTSRD5A1SRD5A2 | |
| SCHEMBL2828425 | 0.74 | CNR1 (0.50) | CNR1SRD5A1SRD5A2 | |
| SCHEMBL4457039 | 0.74 | CNR1 (0.47) | CNR1HTTSRD5A1SRD5A2 | |
| SCHEMBL2270883 | 0.74 | CNR1 (0.43) | CNR1MAPTSRD5A1SRD5A2 | |
| SCHEMBL9141851 | 0.73 | CNR1 (0.43) | CNR1 | |
| SCHEMBL8728950 | 0.73 | CNR1 (0.63) | CNR1SRD5A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487804-B1 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2014-02-26 | — | — | EP | disclosed |
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | disclosed |
| EP-1487804-A2 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | disclosed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | disclosed |
| WO-2003078403-A2 | DERIVES D’AMINOINDAZOLES COMME INHIBITEURS DE PROTEINE-KINASE | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | disclosed |
| US-5438052-A | Cephalosporin derivatives | HOFFMANN-LA ROCHE INC. (US) | 1995-08-01 | — | — | US | disclosed |
| US-5319140-A | Antibiotics | HOFFMANN-LA ROCHE INC. (US) | 1994-06-07 | — | — | US | disclosed |
| EP-0544166-A2 | Cephalosporinderivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1993-06-02 | — | — | EP | disclosed |
| US-5138066-A | Intermediates for cephalosporins with sulfur-containing oxyimino side chain | HOFFMANN-LA ROCHE, INC. (US) | 1992-08-11 | — | — | US | disclosed |
| US-5073550-A | Bactericides | HOFFMANN-LA ROCHE INC. (US) | 1991-12-17 | — | — | US | disclosed |
| US-5036064-A | Antibiotics | HOFFMANN-LA ROCHE INC. (US) | 1991-07-30 | — | — | US | disclosed |
| EP-0303172-A2 | Oxyimino-cephalosporins | F. HOFFMANN-LA ROCHE AG (CH) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | CYP2C8, NR0B2, NR2C2 | AHR 16/4885CNR1 41/4885OPRM1 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.